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Abstract: Osteoarthritis belongs to the most common joint diseases in humans and animals and
shows increased incidence in older patients. The bioactivities of collagen hydrolysates, sulfated
glucosamine and a special fatty acid enriched dog-food were tested in a dog patient study of 52 dogs
as potential therapeutic treatment options in early osteoarthritis. Biophysical, biochemical, cell
biological and molecular modeling methods support that these well-defined substances may act as ef-
fective nutraceuticals. Importantly, the applied collagen hydrolysates as well as sulfated glucosamine
residues from marine organisms were strongly supported by both an animal model and molecular
modeling of intermolecular interactions. Molecular modeling of predicted interaction dynamics was
evaluated for the receptor proteins MMP-3 and ADAMTS-5. These proteins play a prominent role in
the maintenance of cartilage health as well as innate and adapted immunity. Nutraceutical data were
generated in a veterinary clinical study focusing on mobility and agility. Specifically, key clinical
parameter (MMP-3 and TIMP-1) were obtained from blood probes of German shepherd dogs with
early osteoarthritis symptoms fed with collagen hydrolysates. Collagen hydrolysate, a chondropro-
tective food supplement was examined by high resolution NMR experiments. Molecular modeling
simulations were used to further characterize the interaction potency of collagen fragments and
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glucosamines with protein receptor structures. Potential beneficial effects of collagen hydrolysates,
sulfated glycans (i.e., sulfated glucosamine from crabs and mussels) and lipids, especially, eicosapen-
taenoic acid (extracted from fish oil) on biochemical and physiological processes are discussed here
in the context of human and veterinary medicine.
Keywords: osteoarthritis; collagen hydrolysate; sulfated N-acetyl glucosamine; sialic acids; eicos-
apentaenoic acid (EPA); MMP-3; ADAMTS-5
1. Introduction
Osteoarthritis is the most common joint disease in humans and animals and shows in-
creased incidence in older patients. Generally, NSAIDs (Non-Steroidal Anti-Inflammatory
Drugs) are used in the treatment of osteoarthritis [1,2]. However, their use is problematic
in that side effects cannot be excluded and liver and/or kidney damage can be present,
particularly in geriatric patients [2]. Therefore, conventional painkillers are of concern and
alternatives with less or no side effects are being sought. Chondroprotective compounds are
considered to be well tolerated and can be administered unhesitatingly over longer periods
of time. In this context, glucosamine sulfate as well as a special diet with fish oil belongs to
a standard therapy in veterinary medicine. However, collagen hydrolysate has not been
used in the same way of so-called chondroprotective drugs such as glucosamine-based
nutraceuticals [3]. Nevertheless, collagen hydrolysates were analyzed on a submolecular
level in various conditions [4–10]. Clinical studies in which potential effects of collagen
hydrolysate and sulfated glucosamine are directly compared with each other and discussed
in relation to molecular mechanisms are still missing. Beneficial effects of collagen- and
proteoglycan-fragments may be related to specific interactions with receptors like integrins,
especially in the case of collagen fragments [4] and aggrecan [11–13]. Beside these specific
interactions, unspecific contacts between collagen-strands [14–18], proteoglycans and fatty
acids within the extracellular matrix of the cartilage could also play a crucial role when
explaining the therapeutic effects on a sub-molecular size level. Therefore, we assessed
the effect of the applied substances on the cartilage health of animals under study by a
combination of biophysical, biochemical, cell-biological methods and molecular modeling
tools. Such an arsenal of methods has previously been used to assess the beneficial thera-
peutic effects of other bio-medical-relevant macromolecules. These macromolecules are
hyaluronic acid, proteoglycans and phospholipid species [19], sulfated poly- and oligosac-
charides [20–23], polysialic acid and sialic acid containg oligosaccharides [24–28] as well
as lysozymes and anti-microbial peptides in complex with oligosaccharides [29–31]. We
analyzed structure–function relationships and focused on molecular modeling calculations
that would allow us to better understand the details of intermolecular interactions between
sialic acids and relevant proteins. The collagen hydrolysate under study [32–37] was exam-
ined with high resolution NMR experiments, especially, DOSY NMR [4,7]. Additionally,
molecular modeling approaches such as molecular docking and molecular dynamics simu-
lations were carried out in order to obtain more information about the interaction potency
of collagen fragments and sulfated GlcNAc with receptor structures. As a result of this
study we are now able to formulate efficient encapsulation strategies [38–40] for an oral
application of peptides and proteins [41–44]. The concept of this study was to provide a
comparative examination of the potential benefits of nutraceuticals as chondroprotective
agents. Thereby, we tested two specific collagen hydrolysates of bovine and fish origin,
sulfated glucosamine from marine organisms as well as fish oil in lipid and vitamin en-
riched dog food. Collagen-hydrolysate is not a standard therapy in veterinary medicine
for the treatment of osteoarthritis symptoms. We therefore carried out this study in both
dogs and horses which both suffer from similar osteoarthritis symptoms to compare its
efficacy to standard therapy (sulfated GlcNAc). Molecular modeling studies of the applied
nutraceuticals are essential since they provide valuable hints on how these substances
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could influence biochemical processes not only in dogs and horses but as an extension of
this study also in humans.
The aim of this work was to examine and compare the influence of collagen hy-
drolysate and sulfated glucosamine in dogs with osteoarthritis with regard to their ability
to alleviate pain and to reduce the associated clinical orthopedic symptoms. In addition, a
smaller control group (trailing group) was employed in order to avoid a placebo group.
This group was administered a special food developed for joint protection since, due to
ethical considerations, it was necessary that all dogs under study were treated for the
symptoms of early osteoarthritis. The study was combined with cell assays and molecular
modeling calculations with the information obtained, providing a foundation on how the
results of this clinical study may be applied or be useful in the treatment of other species
(e.g., horses) with the same or different collagen hydrolysates (e.g., from fish skin or from
jellyfish collagen).
2. Results
2.1. Drug Administration and Sta†istical Analysis od Dog Treatment
All dogs (Table 1) were examined at the beginning of our study for the characteristic
symptoms of osteoarthritis. The body condition score (BCS) of the dogs is defined according
to Mele [45]. Level 1 (cachectic) to level 9 (obese). Level 5 is considered ideal.
Table 1. Characteristics of studied dogs grouped according to their treatment. The table shows the individual dog number,
the race, the age, the gender, the weight, the disease (coxosteoarthritis—CA, gonosteoarthritis—GA), the degree of lameness
(DL) and the body condition score (BCS). The abbreviations regarding the gender of the dogs are: f: female, fc: female
castrated, m: male, mc: male castrated. * problem with mocing but neither CA nor GA was diagnosed.
Group 1: Collagen Hydrolysate
Dog Nr. Race Age Gender Weight Disease DL BCS
2 Golden Retriever 10 m 43.7 CA 2 8
4 Cairn Terrier 8 m 11 CA stiffmovement 5
6 Boxer mix 13 fc 30.5 CA 1 5
14 Boerboel 3 f 45 GA 2 4
15 Magyar Vizsla 6 fc 24 CA 2 6
19 Leonberger 4 f 51 CA 0 7
20 Mixed breed 8 mc 16 GA 1 8
21 Bernese Mountain Dog 9 fc 38.6 CA 2 6
25 German WirehairedPointer 5 m 46 CA 0 7
26 Shepherd mix 13 fc 34.9 GA 2 6
27 Labrador 3 m 40 CA 0 5
33 Shepherd mix 11 mc 38 CA 3 7
34 German Shepherd 2 f 26 CA 0 4
35 Gordon Setter 10 m 29.4 CA 1 5
37 Poodle 13 fc 9.4 CA 3 7
40 Appenzeller 8 fc 37.8 CA 1 7
45 Samoyed 4 fc 24.8 * 1 4
49 German Shepherd mix 2 fc 23.4 CA 1 5
51 Mixed breed 14 mc 29.7 CA 1 5
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Table 1. Cont.
Group 1: Collagen Hydrolysate
Dog Nr. Race Age Gender Weight Disease DL BCS






Ø 31.1 CA: 15GA: 4 Ø 1.23 Ø 5.7
Group 2: Glucosamine
Dog Nr. Race Age Gender Weight Disease DL BCS
1 Schnauzer mix 5 mc 26.5 CA 2 to 3 6
3 Newfoundland Dog 7 fc 50 GA 2 6
5 Mixed breed 12 f 28 CA 3 7
7 Mixed breed 12 mc 28 CA/GA 3 5
8 Bernese Mountain Dog 6 m 41 CA 2 6
10 Mixed breed 8 m 40 CA 1 6
12 Mixed breed 7 mc 17 CA/GA 1 7
13 Cairn Terrier 8 mc 11 CA stiffmovement 5
16 Beagle 4 mc 16.8 CA 1 6
18 Swiss Mountain Dog 4 m 55 CA stiffmovement 5
22 Labrador 10 mc 32 CA 2 6
23 Newfoundland Dog 10 m 59 CA 2 3
28 Boxer 3 f 30 CA 2 5
29 Kangal 2.5 fc 50 CA 0 6
36 Yorkshire Terrier 6 fc 6.4 CA 2 5
39 German Shepherd 9 m 45.6 CA 1 7
41 Shepherd mix 6 m 32.2 CA 1 5
42 Belgian Shepherd Dog 10 f 36 CA 2 4
44 Ridgeback 1 fc 27.5 CA 2 3
48 Mixed breed 4 mc 29.4 CA 1 3










Ø 1.45 Ø 5.2
GROUP 3: Commercial Joint Diet
Dog Nr. Race Age Gender Weight Disease DL BCS
9 Shepherd mix 8 fc 42 GA 1 5
11 Shepherd mix 7 f 35 GA 2 5
17 German Shepherd 10 fc 34 CA 2 6
24 Mixed breed 9 m 23 CA 1 4
30 German Shepherd–Sennendog-Mix 5 mc 37 CA 1 7
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Table 1. Cont.
GROUP 3: Commercial Joint Diet
Dog Nr. Race Age Gender Weight Disease DL BCS
31 Mixed breed 5 fc 33 CA 0 6
32 GermanShepherd–Husky-Mix 13 fc 40.5 CA 2 7
38 Pomeranian 8 mc 8 CA 2 8
43 Mixed breed 4 mc 38 GA 2 5
46 Golden Retriever 5 mc 29 CA 1 5






Ø 31.4 CA: 8GA: 3 Ø 1.32 Ø 5.8
Fifty-two dogs were treated during the 16 weeks of the therapy period. The treatment
resulted in improvements in agility of animals found in all three groups. To assess pain,
one of the symptoms of OA, and any therapeutic progress, palpation was performed
independently for the left and right femoral joint throughout the study. Notably, a reduction
in tenderness/pain was observed as early as four weeks into treatment (Figure 1). After
16 weeks (the end of the therapy), all groups (including the control group which contains
only the half number of patients) exhibited a reduction in the sensitivity of their femoral
joints to manipulation.
A key indicator of therapeutic value in any trial is the effect of the substances under
study on the quality of life (QOL). We therefore assessed QOL using previously published
guidelines [46–49]. The QOL score of dogs is shown on Figure 2. All substances under
study (collagen hydrolysate, sulfated glucosamine as well as the special dog food enriched
with fatty acids and vitamins) resulted in positive effects on the QOL score. Collagen
hydrolysate led to the most promising results in terms of displaying moderate to minor
symptoms or no joint problems at the focus of study.
Our observations suggest that the collagen hydrolysate applied in this dog-study
contains bio-active fragments that have a beneficial effect on OA symptoms, similar to that
observed for sulfated glucosamine. Cellular studies show that the collagen fragments in
the hydrolysate are responsible for the effects within the extracellular matrix of the joint
tissue. These effects can be supportive, non-supportive or even detrimental [8–10]. In order
to establish the correlation between structure and function of bio-active components of the
collagen hydrolysate applied in our study (Fortigel from Gelita) we further characterized
the relationship by well-established protocols [4,7–10].
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Figure 1. Canine dog patients with beginning OA symptoms were examined at the different time frames, i.e., beginning (0)
and after 4, 8 and 16 weeks of treatment concerning pain in their (A) left or (B) right femoral joint. Pain symptoms during
palpation were examined for all dogs in the three groups according to a clinical standard protocol. Four scores are given: no
pain reaction (blue), minor (orange), strong (red) and extra strong pain reaction (dark red). N on the y-axis corresponds to
the total number of dogs within a group.
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Figure 2. Agility and mobility of dogs with beginning OA symptoms. Marks/color coding: light
blue—no problems, blue—minor problems, orange—moderate problems, red—large problems, dark
red—extremely large problems. The marks were given by the animal-holders at different time-points
(see Figure 1 for details) for the groups of dogs as indicated. These marks correlate with the QOL.
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The grades, i.e., the degrees of lameness (DL) were determined by a veterinary expert.
The orthopedic examination concerning joint pain symptoms (Figure 1) was carried out
first. By presenting the dogs on a plane, non-slip floor covering at walk and trot, the degree
of lameness was assessed. Both the orthopedic examination and the lameness assessment
were documented on the standardized examination sheets by the veterinarian. The entire
movement cycle (walk and trot) including walking upstairs was examined. Since dogs
usually display a mixed lameness, it was not recorded whether this was a support-leg-
lameness or a sloping-leg-lameness. The decisive factor is the degree of lameness, which is
differentiated into five different degrees (zero means not detectable). The grade of lameness
(DL) in dogs (Figure 3) with chronic musculoskeletal disorders is given on a scale from zero
to four. Of the total of 52 dogs, 9 dogs showed no lameness during the entire study period
(4 animals in the collagen group, 3 animals in the glucosamine group and 2 animals in the
joint diet group). All other dogs were permanently or intermittently lame or had a stiff gait.
DL 4 could not be determined in any of the test subjects. At week 0 (initial examination) a
stiff gait could be observed in 3 dogs, DL 1 was present in 16 dogs and DL 2 was present in
22 patients. DL 3 was prevalent in two dogs. At week 16 (final examination), DL 3 was
present in one dog, DL 2 in 15 animals, DL 1 in 11 animals and a stiff gait pattern in 2 dogs.
A total of 19 dogs show no lameness (DL = 0).
Four dogs had to be removed from the study and were therefore not included in the
final examination. No statistically significant differences were found in the distribution of
the DL between the groups (p-value for week 0: 0.35; week 4: 0.85; week 8: 0.36; week 16:
0.59). There were roughly the same number of dogs free of lameness in all groups, with
mild or moderate lameness. The lameness of the dogs decreased significantly during the
investigation period (p-value 0.015), i.e., at the end of the investigation period significantly
more animals were free of lameness than at the beginning of the investigation. The collagen
and glucosamine groups had a comparable composition in regard to the degree of lameness.
There were no statistically significant differences. Within the three groups, the distribution
of the DL was shown as presented in Figure 3. In the group following the joint diet, only
minor changes in the DL were found during the study period. During the final examination
three animals were free of lameness, while at the beginning there were two in group 3.
Within the other two groups, significantly more animals were free of lameness at week 16.
In the younger dogs (2 to 5 years old), a relatively large number of them were still running
free of lameness, despite the x-ray evidence of arthritis. With increased age of the animals,
the number of dogs showing lameness increased. In particular, the proportion of dogs with
DL 2 was frequently represented with advancing age. When comparing group 1 (collagen)
with group 2 (glucosamine) at the end of the study period 9 in group 1 and 7 in group 2 are
completely free from lameness.
The distribution of grades in regard to an assessment of complaints after invalidation/
burden is shown differentially by color at 4-week intervals during the sixteen-week study
period (Figure S1). The complaints of all dogs under study after prolonged exposure
were rated with an average mark of 2.92 at the beginning of the study period. In the
collagen, glucosamine and joint diet groups the average mark was initially 2.64, 3.38 and
2.16, respectively. At the end of the study period, the average mark of all dogs was rated
2.42. In the individual collagen, glucosamine and joint diet groups, the average marks were
1.93, 2.8 and 2.46, respectively. As the diagram shows, the dogs in the glucosamine group
tend to have more severe symptoms after prolonged exercise.
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Figure 3. Lameness of dogs with beginning OA symptoms. The grades were given by a veterinarian
not further involved in the study but viewing and evaluating the video footage at both the beginning
and end of the therapy. Grades/color coding: light blue—no problems (M0), blue—minor problems
(marked S —stiff movement), yellow—moderate problems (M1), orange—large problems (M2),
dark red—extremely large problems (M3).
The distribution of jumping ability is shown differentially by color at 4-week intervals
during the sixteen-week study period (Figure S2). The average mark for jumping was
rated with a mark of 3.24 at the beginning of the study period. In the individual collagen,
glucosamine and joint diet groups the average marks were 3.0, 3.63 and 2.86, respectively.
At the end of the study period the average mark was 2.6, with the collagen, glucosamine
and joint groups displaying marks 2.34, 2.79 and 2.68, respectively. Figure S2 shows that
the dogs in the glucosamine group tended to have more discomfort when jumping with a
smaller number of animals jumping completely symptom-free.
The distribution of back pain sensitivity as revealed by the patient holders is shown
differentially by color at 4-week intervals during the sixteen-week study period (Figure S3).
The touch sensitivity of the back was rated with an average mark of 1.85 at the beginning
of the study period. In the collagen, glucosamine and joint diet groups the averages were
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1.89, 1.85 and 1.78, respectively. At the end of the study period, the average was 1.59
and characterized by a certain degree of homogeneity. At the same time the collagen,
glucosamine and joint diet groups attained marks of 1.69, 1.48 and 1.63, respectively.
The distribution of joint pain sensitivity is shown differentially by color at 4-week
intervals during the sixteen-week study period (Figure S4). The distribution of grades is
shown differentially by color at 4-week intervals during the sixteen-week study period.
The touch sensitivity of the affected joint was rated with an average mark of 2.19 at the
beginning of the study period. In the collagen, glucosamine and joint diet groups the
average was 2.63, 1.78 and 2.22, respectively. At the end of the study period the average
was 1.97. In the collagen, glucosamine and joint diet the sensitivity score was 2.4, 1.63 and
1.94, respectively. By a descriptive point of view, a decrease in the sensitivity to touch was
found in the collagen and glucosamine groups during the study. Overall, the difference in
joint pain sensitivity between the groups was not striking at any time of the investigation
(p-value 0.23 week 0 and 0.21 week 16). However, a possible trend is apparent with touch
sensitivity decreasing for all three groups over the course of the study (grade 1.5–2.49).
The HCPI (Helsinki Chronic Pain Index [50]) of dog patients at the beginning and after
16 weeks of treatment is summarized in Table 2. We compared our data with the results of
an article about the ameliorative effects of omega-3 concentrate in managing coxofemoral
osteoarthritic pain in dogs [51]. Scores in the HCPI range from zero to four points, with
four points corresponding to highest degree of pain. The points were averaged for each
group with the expectation that with successful therapy the average score would decrease.
Table 2. HCPI (Helsinki Chronic Pain Index) of dog patients at the beginning and after 16 weeks of
Collagen hydrolysate, or Glucosamine or Special dog-food treatment.
Behavior
Collagen






Mind and mood 0.5 0.26 0.55 0.35 0.78 0.67
Vocalization 0.36 0.43 1 0.88 0 0
Joy of playing 1.31 1 1.72 1.35 1.25 1
Joy of running 1.5 0.76 1.83 0.94 1.78 1
Will to trot 1.56 1 1.89 1.47 1.33 0.89
Will to gallop 2.06 1.5 2.33 1.82 2.22 2
Jumping 2.25 1.71 2.72 2 2.22 2.11
Laying down 1.44 1.29 1.56 1.29 1.78 1.67
Standing up 2.13 1.79 2.61 2 2.33 2.22
Difficulty moving
after a long break 2.38 2.14 2.61 1.94 2.22 2
Difficulty moving
after exercise 2.07 1.58 2.94 2.5 2 2
The impact of drugs and nutritional supplements on the mobility of randomly selected
dogs of the study (Table 3) was evaluated and documented by video at both the beginning
and end of the therapy. Our current observations are in full agreement with a horse-study
recently published [35].
Mar. Drugs 2021, 19, 542 11 of 30
Table 3. Characteristics of randomly selected dogs shown in video presentation.
Dog Name
(#Number) Treatment Breed Age (Years) Weight (kg)
Buddy (#1) glucosamine Schnauzer-mix 5 26.5
Cora (#3) glucosamine Newfoundland Dog 7 50
Sarabi (#14) collagen hydrolysate Boerboel 3 45
Tobi (#20) collagen hydrolysate Mixed-breed 8 16
Emma special dog-food withlipids and vitamins German shepherd-mix 7 35
Representative videos (mp4 format) for two patients from the sulfated glucosamine
group, two from the collagen hydrolysate group and one dog from the control group are
available for download from the Supplementary Material.
Dog-patient handlers were able to easily perceive that dogs in the early stages of OA
already exhibited difficulty with stair climbing. The videos clearly display this observation
and demonstrate that sixteen weeks of therapy had a positive effect on the ability of
these dogs to climb stairs along with no new outwardly discernable negative aspects or
progression of disease.
2.2. X-ray and Statistics
X-ray data were recorded from each dog at the beginning of the study. There was no
significant statistical deviation in the x-ray data when comparing the left with the right
hip joint (Figure S6). This is also the case when comparing the left and the right knee joint
(p-value left knee joint: 0.12; right knee joint: 0.13; left hip joint: 0.11; right hip joint: 0.15).
We also recorded x-ray data from selected dogs at the end of the study. The number of
dogs was limited due to the necessity of obtaining the permission of the patient holders.
Furthermore, sedation of the dogs was necessary for X-ray imaging and our goal was
always to reduce unecessary risk in the dogs under study. While the symptoms of pain
and the QOL improved for a subset of the dogs under study, the X-ray data revealed that
the damage to the bone in the affected joints was not improved with any of the treatments.
In relation to the X-ray analysis measurements of the left thigh circumference at the
time of the initial examination resulted in an arithmetic mean of 39.7 cm (all patients
combined). The smallest value was 24 cm, the largest 56 cm. The standard deviation
was 8.1. A mean value of 38.5 cm was calculated for the collagen group, 39.6 cm for the
glucosamine group and 42.5 cm for the joint diet group. At the final examination, the values
were recorded in 46 patients. The mean value was 41.1 cm; the wingspan ranged from
21 cm to 57 cm. The mean value for the collagen group was 40.4 cm, for the glucosamine
group it was also 40.4 cm and for the joint diet group it was 44.0 cm. The right thigh
circumference at the time of the initial examination averaged 39.6 cm. In the collagen group
it was 38.4 cm, in the glucosamine group it was 39.6 cm and in the joint diet group it was
42.2 cm. The smallest value was 24 cm, the largest 57 cm. During the final examination,
the arithmetic mean of 40.98 cm was determined for all tested patients, 40.5 cm for the
collagen group, 40.1 cm for the glucosamine group and 43.9 cm for the joint diet group.
The wingspan ranged from 21 cm to 57 cm. The mean difference between the right and left
thigh muscles at the initial examination, all groups combined, was 1.1 cm. The wingspan
ranged from no difference up to 6 cm. In the collagen group the mean value was 1.3 cm, in
the glucosamine group 0.9 cm, and in the joint diet group 1.1 cm. At the final examination,
the arithmetic mean in the aggregation of all groups was 0.45 cm, in the collagen group
0.47 cm, in the glucosamine group 0.42 cm and in the joint diet group 0.5 cm. For the size
of the left thigh muscles, the p-value for time was 0.0037 and the p-value for the groups
was 0.67, i.e., there were only small differences between the groups that are not statistically
significant. With regard to time, however, significant differences could be found, which
Mar. Drugs 2021, 19, 542 12 of 30
means indicating a statistically significant increase in muscle size during the study period.
The size of the right thigh muscles was similar. There were no statistically significant
differences between the groups (p-value 0.68). Here, too, there was a significant increase
in muscle size over time (p-value 0.01). The difference between the right and left thigh
muscles (delta value) also shows no decisive differences in relation to the two main groups
(p-value 0.33). Over time, however, there was a statistically significant reduction in the
difference between right and left muscle circumference (p-value 0.0001).
X-ray data and measurements of the muscle circumferences provide physically mea-
surable data, however, observation concerning pain symptoms and the mobility are also of
high importance in the evaluation of the efficacy of nutraceuticals. The data were collected
by the patient-holders (Figure 2 and Figures S1–S5) but also by experienced veterinarians
(Figures 1 and 3) at the four examination times (initial examination, first examination—4
weeks, second examination—8 weeks, final examination—16 weeks).
2.3. Cell Biology Tests and Blood Parameters
The differentiation of canine as well as of equine chondrocytes was studied in the
absence and in the presence of collagen hydrolysates and proteoglycan fragments. The
distinct time-dependent differentiation pattern (e.g., with respect to the known sialic acid
galactose linkage at the end of the saccharide chains of the corresponding glycoproteins is
well established [24], and can be used to test the respective impact of various substances in
cell culture very precisely [10]. A representative image displaying the expected pattern for
equine chondrocytes grown on collagen is presented in Figure 4A.




Figure 4. (A) Equine chondrocytes were grown on collagen media. The cell nuclei are highlighted by DAPI staining with 
the growing collagen strands around the nuclei stained in light green. (B) The polysialic acid molecules on progenitor cells 
from the subventricular zone of the mouse brain are colored in red. The glia cells are colored in dark green. 
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a progenitor cell assay from cells of the subventricular zone of the mouse brain. This indi-
cates that sialic acid staining is a feasible method to control the collagen dependent differ-
entiation of glia. 
Blood samples were analyzed for a homogenous group of dog patients (23 German 
Shepherd dogs) in which collagen hydrolysate was tested as a food supplement. Previous 
studies were focused on a correlation between MMP-3 plasma levels and MMP-3 synovia 
levels for dogs suffering from osteoarthritis [46,47]. Since MMP-3 is a highly proteolytic 
enzyme, enhanced breakdown of cartilage tissue in the German shepherd dog OA group 
could occur via degradation of collagen types II, IX, X [54] and aggrecan [55]. Addition-
ally, TIMPs are known inhibitors of MMP within tissues. We therefore examined MMP-3 
(Figure 5A) and TIMP-1 levels (Figure 5B) in a back-to-back study of 23 German Shepherd 
dogs (guard and protection dogs of the police) which were fed over a time of 8 weeks with 
the same collagen hydrolysate provided to the 20 dogs in the collagen hydrolysate group 
described above. The analysis of MMP-3 and TIMP-1 levels (presented in Figure 5) was 
performed in accordance with Parkkonen et al. [56]. Notably, MMP-3 levels were signifi-
cantly reduced (p = 0.01) after 8 weeks of treatment. We did not find a significant alteration 
in TIMP-1 levels during this same period. 
The data presented here also support the data gained earlier at Tierärztliche 
Hochschule Hannover [49]. Our results suggest that sulfated and non-sulfated glucosa-
mines and small collagen fragments may have a direct influence on the activity of matrix 
metalloproteinases. Given this result, allosteric inhibition and stimulation as well as com-
petitive inhibition were considered as an additional mechanism to be investigated when 
using collagen hydrolysates or proteoglycan fragments, i.e., sulfated and non-sulfated 
glucosamines as nutraceuticals. 
Figure 4. (A) Equine chondrocytes were grown on collagen media. The cell nuclei are highlighted by DAPI staining with
the growing collagen strands around the nuclei stained in light green. (B) The polysialic acid molecules on progenitor cells
from the subventricular zone of the mouse brain are colored in red. The glia cells are colored in dark green.
The induction of multi-directional differentiation processes of equine and canine chon-
drocytes strongly depends on the kind of collagen hydrolysate [10], as shown in Figure 4A
with the collagen hydrolysate under study. Furthermore, the nerve cell progenitor assay
can act as a test system to control the sialic acid dependent impact of collagen fragments on
cell migration and differentiation [24,26,52,53]. Figure 4B shows an example of a progenitor
cell assay from cells of the subventricular zone of the mouse brain. This indicates that sialic
acid staining is a feasible method to control the collagen dependent differentiation of glia.
Blood samples were analyzed for a homogenous group of dog patients (23 German
Shepherd dogs) in which collagen hydrolysate was tested as a food supplement. Previous
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studies were focused on a correlation between MMP-3 plasma levels and MMP-3 synovia
levels for dogs suffering from osteoarthritis [46,47]. Since MMP-3 is a highly proteolytic
enzyme, enhanced breakdown of cartilage tissue in the German shepherd dog OA group
could occur via degradation of collagen types II, IX, X [54] and aggrecan [55]. Additionally,
TIMPs are known inhibitors of MMP within tissues. We therefore examined MMP-3
(Figure 5A) and TIMP-1 levels (Figure 5B) in a back-to-back study of 23 German Shepherd
dogs (guard and protection dogs of the police) which were fed over a time of 8 weeks
with the same collagen hydrolysate provided to the 20 dogs in the collagen hydrolysate
group described above. The analysis of MMP-3 and TIMP-1 levels (presented in Figure 5)
was performed in accordance with Parkkonen et al. [56]. Notably, MMP-3 levels were
significantly reduced (p = 0.01) after 8 weeks of treatment. We did not find a significant
alteration in TIMP-1 levels during this same period.




Figure 5. (A) MMP-3 and (B) TIMP-1 levels in 23 German shepherd dogs with early OA in which their diet was supple-
mented with collagen fragments. The concentration values (different scaling for MMP-3 and TIMP-1) at the y-axis corre-
spond to ng/mL. Shown are the levels at the beginning and after 8 weeks of treatment. Data in box plots are presented as 
medians, 25th and 75th percentiles (boxes), and 10th and 90th percentiles (whiskers). 
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Our studies indicated that pain reducing effects are detectable by an evaluation of 
the mobility and agility of the animals under study. Furthermore, biochemical parameters 
are also altered as found in our analysis of the blood-probes with respect to osteoarthritis 
markers (e.g., TIMP-1, MMP-3). These observations are probably related to the occurrence 
of certain bio-active collagen fragments within the hydrolysates. It was therefore of inter-
est to determine whether the positive effect on cartilage health for dog patients with be-
ginning osteoarthritis symptoms can be correlated with the applied collagen fragment 
mixture. We therefore conducted TOCSY, NOESY and DOSY NMR experiments as de-
scribed previously. Since the collagen hydrolysates differed in their composition, we fur-
ther characterized them to provide a more detailed molecular analysis. In the present 
study, we used TOCSY and NOESY experiments to identify specific amino acid residues 
(e.g., Arg residues) of these bio-active compounds (Figure 6). This type of analysis allowed 
us to characterize the collagen hydrolysate unambiguously. The NMR results indicate that 
the size-range of the collagen fragments in the collagen hydrolysate food supplement is 
between 2.9 and 8.1 kDa, with no triple helical collagen structures present. Since the col-
lagen hydrolysates differed in their composition, we further characterized them to pro-
vide a more detailed molecular analysis. In the present study, we used DOSY to identify 
specific amino acid residues (e.g., Arg residues) of these bio-active compounds (Figure 7). 
This type of analysis allowed us to characterize the collagen hydrolysate unambiguously. 
Figure 5. ( ) ( ) TIMP-1 levels in 23 German shepherd dogs with early OA in which their di t was supplement d
with collagen fragments. The concentration v lues (diff rent scali g for MMP-3 and TIMP-1) at the y-axis correspond to
ng/mL. Shown are the levels at the beginning and after 8 weeks of treatment. Data in box plots are presented as medians,
25th and 75th percentiles (boxes), and 10th and 90th percentiles (whiskers).
The dat presented here also support the data gained earlier at Tierärztliche Hochschule
Hannover [49]. Our results suggest that sulfated and non-sulfated glucosamines and small
collagen fragments may have a direct influence on the activity of matrix metalloproteinases.
Given this result, allosteric inhibition and stimulation as well as competitive inhibition
were considered as an additional mechanism to be investigated when using collagen
hydrolysates or proteoglycan fragments, i.e., sulfated and non-sulfated glucosamines
as nutraceuticals.
2.4. NMR Analysis of Fortigel Collagen Hydrolysate
Our studies indicated that pain reducing effects are detectable by an evaluation of
the mobility and agility of the animals under study. Furthermore, biochemical parameters
are also altered as found in our analysis of the blood-probes with respect to osteoarthritis
markers (e.g., TIMP-1, MMP-3). These observations are probably related to the occurrence
of certain bio-active collagen fragments within the hydrolysates. It was therefore of interest
to determine whether the positive effect on cartilage health for dog patients with beginning
osteoarthritis symptoms can be correlated with the applied collagen fragment mixture. We
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therefore conducted TOCSY, NOESY and DOSY NMR experiments as described previously.
Since the collagen hydrolysates differed in their composition, we further characterized
them to provide a more detailed molecular analysis. In the present study, we used TOCSY
and NOESY experiments to identify specific amino acid residues (e.g., Arg residues) of
these bio-active compounds (Figure 6). This type of analysis allowed us to characterize
the collagen hydrolysate unambiguously. The NMR results indicate that the size-range of
the collagen fragments in the collagen hydrolysate food supplement is between 2.9 and
8.1 kDa, with no triple helical collagen structures present. Since the collagen hydrolysates
differed in their composition, we further characterized them to provide a more detailed
molecular analysis. In the present study, we used DOSY to identify specific amino acid
residues (e.g., Arg residues) of these bio-active compounds (Figure 7). This type of analysis
allowed us to characterize the collagen hydrolysate unambiguously.




Figure 6. NOESY NMR spectrum of the collagen hydrolysate Fortigel® from Gelita applied in our dog study. F1 and F2 
are the frequency axes which display both the chemical shifts of the aromatic- and NH-region of the collagen protons (in 
ppm). 
Figure 6. NOESY NMR spectrum of the collagen hydrolysate Fortigel® from Gelita applied in our dog study. F1 and F2 are
the frequency axes which display both the chemical shifts of the aromatic- and NH-region of the collagen protons (in ppm).




Figure 7. (A,B) Parts of a two-dimensional DOSY spectrum of the used collagen hydrolysate, Fortigel®. The aromatic- and 
NH-region (A) as well as the aliphatic region (B) were used to determine the diffusion constant. F2 displays the chemical 
shift of the collagen protons (in ppm). F1 is the frequency axis which provides information about the diffusion constant of 
the collagen fragments. 
  
Figure 7. (A,B) Parts of a two-dimensional DOSY spectrum of the used collagen hydrolysate, Fortigel®. The aromatic- and
NH-region (A) as well as the aliphatic region (B) were used to determine the diffusion constant. F2 displays the chemical
shift of the collagen protons (in p m). F1 is the frequency axis which provides information about the iffusion constant of
the collagen fragments.
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2.5. Molecular Modeling
We utilized the available PDB structural data for MMP-3 (2JT6.pdb) and ADAMTS-
5 (2RJQ.pdb) as the starting geometries for molecular modeling tasks. Although their
experimental geometries also exhibit ligands in their binding sites, we were also interested
in how sialic acid and GlcNAc in standard and sulfated forms can bind to MMP-3 and
ADAMTS-5. Thus, we were equally interested in the prediction of all possible binding sites
(BS) for these two proteins. Three binding sites were predicted using the SiteMap program
for MMP-3, whereas the prediction of BS for ADAMTS-5 was three times higher. The
number of predicted binding sites is in agreement with the size/weight of these proteins
(18.54 kDa for MMP-3 and 42.84 kDa for ADAMTS-5).
In the next step, we calculated how N-Acetyl glucosamine (GlcNAc) and N-Acetyl
neuraminic acid (Neu5Ac) (both in standard and sulfated forms) can bind into all predicted
binding sites. We used the Glide program to determine binding poses and the energetics of
binding for the four carbohydrates.
The Glide analysis for all binding sites and all carbohydrates resulted in more than
one thousand protein–ligand complexes. Table 4 presents the lowest energy binding poses
for MMP-3 and ADAMTS-5.
Table 4. Summary of the lowest docking scores for carbohydrate–protein complexes for all predicted
binding sites. The lower value in the comparison standard versus the sulfated form of the carbohy-
drates is shown in italics; the lowest binding scores in comparison to the four carbohydrates in the
particular binding site are highlighted in bold. Carbohydrates bound to the MMP-3 binding site and




Site GlcNAc GlcNAc-sulf Neu5Ac Neu5Ac-sulf
MMP-3 2JT6
BS1 −8.16 −8.23 −11.48 * −8.76
BS2 −9.20 −9.12 −8.68 −9.43 *
BS3 −5.24 −6.27 −6.88 −7.42 *
ADAMTS-5 2RJQ
BS1 −6.28 −6.96 −7.61 −8.09*
BS2 −7.05 −7.94 −9.00 −9.22 *
BS3 −5.94 −5.45 −5.87 −5.78
BS4 −7.25 −9.16 −8.61 −9.35 *
BS5 −6.99 −5.73 −8.61 −7.73
BS6 −4.47 −4.89
BS7 −7.07 −7.31 −8.35 −8.88
BS8 −6.07 −5.85 −8.86 −8.19
BS9 −6.68 −6.81 −8.82 −7.93
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Figure 8. Glucosamines in binding sites of (A) MMP-3 (2JT6.pdb) and (B) ADAMTS-5 (2RJQ.pdb). The protein–ligand 
complexes are shown as a ribbon representation in the left set of figures; the protein surfaces (colored according the elec-
trostatic potential) zoomed into binding sites are in the middle set of figures whereas the details of the protein–ligand 
interaction profiles are visualized in the right set of figures. 
The ribbon presentation for MMP-3 together with the ligand–protein interaction 
analysis is illustrated in Figure 8A. Equivalent figures for ADAMTS-5 are presented in 
Figure 8B. 
It is interesting to note Neu5Ac is predicted to bind preferably (apart from BS3 of 
ADAMTS-5) over GlcNAc. The sulfated forms of glucosamines in most cases bind better 
than the unsulfated molecules. The exception is Neu5Ac in BS1 of MMP-3. This is a special 
case (illustrated in Figure 8A-BS1) because this binding site appears below the protein 
loop and the carbohydrate molecule also interacts with the amino acids of the loop. 
The next modeling step dealt with explicit modeling of the proteins with collagen 
fragments. We used the HEX program here to generate (based on shape and electrostatics 
complementarity) around 100 protein–collagen complexes for both proteins. The lowest-
energy forms from the HEX modeling were used as the starting structures for molecular 
dynamics (MD) simulations. 
MD simulations were performed in a water environment in order to evaluate the 
stability of the protein–collagen complexes. Figure 9 presents part of the results from a 50 
Figure 8. Glucosamines in binding sites of (A) MMP-3 (2JT . db) and (B) ADAMTS-5 (2RJQ.pdb). The protein–ligand
complexes are shown as a ribbon representation in the left set of figures; the protein surfaces (colored according the
electrostatic potential) zoomed into binding sites are in the middle set of figures whereas the details of the protein–ligand
interaction profiles are visualized in the right set of figures.
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The ribbon presentation for MMP-3 together with the ligand–protein interaction
analysis is illustrated in Figure 8A. Equivalent figures for ADAMTS-5 are presented in
Figure 8B.
It is interesting to note Neu5Ac is predicted to bind preferably (apart from BS3 of
ADAMTS-5) over GlcNAc. The sulfated forms of glucosamines in most cases bind better
than the unsulfated molecules. The exception is Neu5Ac in BS1 of MMP-3. This is a special
case (illustrated in Figure 8A-BS1) because this binding site appears below the protein loop
and the carbohydrate molecule also interacts with the amino acids of the loop.
The next modeling step dealt with explicit modeling of the proteins with collagen
fragments. We used the HEX program here to generate (based on shape and electrostatics
complementarity) around 100 protein–collagen complexes for both proteins. The lowest-
energy forms from the HEX modeling were used as the starting structures for molecular
dynamics (MD) simulations.
MD simulations were performed in a water environment in order to evaluate the
stability of the protein–collagen complexes. Figure 9 presents part of the results from a
50 ns simulation. The structure at the start of simulation plus 10 time-dependent structures
extracted from the saved simulation trajectory at 5 ns intervals were superposed and are
shown on Figure 9 in order to present the time-evolved conformational changes. The
“simulation quality analysis” of Maestro/Desmond (Figures 8C and 9A) indicated that the
standard deviation of all analyzed parameters like total energy, potential energy or volume
is below 0.01% of the average value variables that were a result of the MD simulations.
PLIP analysis and the consequent Access processing of the MD trajectory geometries
allowed a comparison of overall hydrogen bonding versus hydrophobic interactions for
both MMP-3/collagen and ADAMTS-5 collagen. Similar data were obtained with both
systems with hydrogen bonding predominating with an incidence of 68% for ADAMTS-5
and 66% for MMP-3 complexes. In comparison, hydrophobic interaction stabilization
accounted for 34% in the case of MMP-3 and 32% in the case of ADAMTS-5.
The carbohydrate entity present on the protein surface in the case of ADAMTS-5
interacts with the collagen structure as shown in Figures 8D and 9B. Accordingly, the
sulfate groups present at the glycan chains of proteoglycans can mediate interactions with
collagen—triple helix structures of collagen present in cartilage.
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energy of the simulated system; dark blue—potential energy; violet—temperature; black—pressure; dark green—volume.
(B,D)—Superposition of protein–collagen structures resulted from the MD simulations. Only selected structures (shown as
ribbons) of the supramolecular complexes saved in 5 ns time intervals are visualized. The ligands of the proteins are shown
in ball and stick models (grey carbons), whereas the GlcNAc present in ADAMTS-5 is shown with green carbons. The
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The water molecules/ions present in the solvation box are not visualized.
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3. Discussion
The ability to treat early stages of osteoarthritis with minimal side effects is a prime
consideration in any treatment. Our study was focused on candidate dogs with early onset
osteoarthritis.
Symptoms of pain noted during palpation by the attending veterinarian, mobility
and agility marks evaluated by the patient-holders as well as an independent video-based
assessment of the mobility of all the dogs in the study are displayed in Figures 1–3. As
revealed by the data in the glucosamine group and even more clearly in the collagen
hydrolysate group: the lameness of dogs with mild symptoms clearly improved, Figure 3.
Intermolecular interactions of the glucosamine entity present on the ADAMTS-5 protein
surface (as presented in Figure 9B) can influence the triple-helical structure of collagen
present in the cartilage. Beside the administration of glucosamine sulfate the interactions
of collagen fragments with matrix metalloprotease–carbohydrate complexes underline the
importantance of glycobiological aspects of cartilage health.
A visible difference in the thigh musculature between healthy and diseased legs
clearly decreased in all three groups. Additionally, there was a striking reduction in pain
during palpation of the knee joint in both the collagen group and glucosamine groups.
During the study period, this was accompanied by a significant reduction in symptoms
while standing, climbing stairs, jumping and after prolonged strain. An obvious reduction
in touch sensitivity of the affected joint and the spinal cord, respectively, as well as an
obvious increase in running pleasure was also found in these two groups. Similarly, a clear
reduction in the symptoms while standing and a reduced touch sensitivity of the affected
joint and an increase in running pleasure was found in the joint diet group. This group
displayed minimal improvement in the other four parameters. The HCPI (Helsinki Chronic
Pain Index; Table 2) and the QOL (Quality of Live score) improved in all three groups. The
observed clinical improvements, particularly through the administration of glucosamine
sulfate and collagen hydrolysate, indicate a positive effect for these two compounds.
It was impossible to detect the effect of the standard dog food in this study. In order to
observe the effect of standard food a placebo group has to be created, comprising dogs fed
in an ordinary way. This was forbidden due the fact that the animals were sick and needed
to be treated. Consequently, group 3 was entitled as commercial joint diet group. It was
the fatty acid-related group where we expected healing success as well. The food in group
3 was changed completely (no collagen or glucosamine enrichment) and the dogs were
administered with power food only. The food for this group can be entitled as power food
because it was designed to contain valuable fatty acids. The feeding in group 1 and 2 was
different. The dogs obtained standard dog food but enriched with collagen hydrolysate
(Group 1) or sulfated glucosamine (Group 2). While the feeding within Group 2 or Group
3 matched standard feeding protocols, fish-oil-enriched collagen hydrolysate feeding is
more or less a novel protocol. Independently of the therapeutic options used for Groups
1 to 3, the beneficial effect of treatment (but slightly different) was monitored in all three
groups of the dogs.
Our combined clinical, cell biological, biochemical, biophysical and molecular model-
ing approach on canine and equine patients is a feasible strategy to answer a number of
questions related to collagen hydrolysates, sulfated glycans and lipids as chondroprotective
food supplements. Articular cartilage destruction is mediated by the loss of collagen type II
and proteoglycans and this loss is a characteristic feature of osteoarthritic (OA) symptoms.
Our results show that it is possible to correlate the influence of collagen hydrolysates on
cartilage tissue [32–34] through specific biochemical pathways and cell–biological pro-
cesses [4,7,8]. We found that collagen hydrolysates were able to alter the levels of MMP-3
without changing the level of TIMP-1 (Tissue Inhibitors of MetalloProteinases-1; data not
shown). In addition, we recognized the involvement of collagen hydrolysates and sulfated
glucosamine in several key biochemical processes which are directly correlated with carti-
lage health. As noted, collagen hydrolysates contain mixtures of collagen fragments of vari-
ous length. We show here that modeling is a useful tool in evaluating specific interactions in
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protein binding sites and interactions between these proteins and collagen fragments. The
impact of sulfation in the case of glucosamine is discussed here in detail. In comparison to
sulfated GlcNAc, we analyzed the interactions of sulfated Neu5Ac, which is an interesting
member of the sialic acid family with bio-medical relevance [24,25,27,28,30,57]. In addition,
the effect of chondroprotective collagen hydrolysate of fish or jellyfish origin on cell cul-
tures is similar to the effect of collagen hydrolysate of bovine origin used in the present dog
study. We note that the EU Community approval/registration of fish or jellyfish originated
collagen hydrolysate is not completed yet. No doubt further investigation on the impact
of these interactions on protein activity in relation to targeting diseases will be crucial in
further evaluating their effect on the extracellular matrix and therapeutic value.
Cartilage markers (MMP-3 and TIMP-1, Figure 5A,B) were analyzed over a time period
of 8 weeks from a homogenous group of 23 German Shephard dogs of nearly the same
weight. This was important in order to determine a daily dose of 20 g. One could argue
that a dose for smaller dogs with a lower body weight has to be adapted to these patients.
Since collagen hydrolysate and sulfated glucosamine are nutrition supplements without
any toxic effect, overdosing in smaller dogs theoretically could have led to increased
positive effects. This, however, was not observed during our study. Cell assays, molecular
modeling studies, examination of eight horses and one dog in a long-time study were
necessary in order to find out in which way our results can be extended to different species
(including humans) and to collagen hydrolysates from other resources (e.g., fish skin and
jellyfish). Therefore, Figure 4A,B is not shown in order to document a state before and
after a treatment with collagen hydrolysate. The effects of collagen hydrolysates on equine
cells have been documented in detail in the literature (Raabe et al., 2010) [10]. It is also
feasible to analyze the impact of collagen hydrolysate on the migration of nerve cells
(Zhang et al., 2016) [26]. In this context Figure 4B demonstrates that it was possible to
observe the differentiation of stem cells treated with collagen hydrolysate by staining with
polysialic acid.
To figure out whether the positive effects of collagen hydrolysate may be detectable or
useful in other species that display osteoarthritis related problems in their movements, we
also treated selected horses (50 g/day for a normal-sized horse and 25 g/day for a smaller
horse e.g., a Shetland pony) In the case of a Holstein horse, a Hanoverian horse, an Arabian
horse, an American Quarter horse, a Trotter, an English Blood horse, a Shetland pony
and a Trakehner horse positive responses were detectable with corresponding methods as
discussed here for the dog patients.
Overall, all three therapies have a positive effect on dogs’ health, justifying their indi-
vidual use. However, the data presented here along with the supplementary data indicated
that sulfated glucosamine and collagen hydrolysate used as supplementary nutraceuticals
are more effective than high-quality dog food alone, with collagen hydrolysate and sulfated
glucosamine having similar positive effects on cartilage health. However, importantly
the data indicate that supplementing a dog’s diet with collagen has the greatest effect on
reducing lameness, thus suggesting that the goal of increasing collagen levels should be
incorporated into a treatment regime that targets the OA symptom of lameness.
4. Materials and Methods
4.1. Dog Osteoarthritis and Drug Administration
Dogs were chosen based on a thorough anamnestic workup, a general and an ortho-
pedic examination (including an X-ray examination) as well as a blood draw. Subsequently,
52 dogs were randomized into three groups. 20 dogs received collagen hydrolysate, 21
dogs received glucosamine sulfate and 11 dogs received the special diet. The animals in all
three groups were fed with the supplements or the special diet over a period of 16 weeks.
During this time, follow up examinations were carried out after 4, 8 and 16 weeks. Data
from a separate study of 23 German Shepard dogs were used in our study to analyze the
MMP-3 data over a time-period of 8 weeks. Furthermore, 8 horses (including a pony) were
examined in order to determine the efficacy of this treatment design in other species.
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Various dogs with early osteoarthritis (OA) were examined in a randomized clinical
study examining the therapeutic effect of nutraceuticals. Specifically, the impact of (A)
a collagen hydrolysate, (B) tablets of sulfated glucosamine and (C) a high-quality dog-
food, i.e., Hills-JD (containing vitamins and enriched with fatty acids, especially EPA)
on joint health was evaluated. The dogs were fed Hills-JD instead of a placebo, since
the dogs already displayed osteoarthritis symptoms and were therefore already being
treated accordingly. The main lipid-component of HillsJD is eicosapentaenoic acid (EPA)
which is enriched in sea-fishes such as salmon and herring. The administered peptides,
carbohydrates and lipids were delivered via the gastro-intestinal tract into the blood-
stream and administered in this way to the crucial target tissues in the organism. A dose
of 20 g collagen hydrolysate was administered per day and dog patient (based on the
daily collagen requirements in food for wolves). The dose was not reduced for smaller
dogs since a higher amount of this nutraceutical is completely harmless (as tested in a cell
biological assays).
Sulfated GlcNAc in the form of tablets, collagen hydrolysate from Gelita dry powder,
Hills JD high quality dog-food were used to target dogs’ osteoarthritis. Fish collagen
hydrolysate is produced by the skin of deep water ocean fish (cod, haddock and pollock).
The fish collagen (Norland Products Inc., Cranbury, NJ, USA) consisted primarily of alpha
1 and alpha 2 chains in a 2:1 ratio with a MW between 4.5 and 21 kDa [7,10].
The QOL-score (Quality of life) combines the mood of the animal, its mobility and
agility, joy of playing, sounds of pain and problems with climbing stairs. Dog-patient
handlers were provided with a questionnaire which evaluated the QOL score. In addi-
tion, to remove any perceived bias, a veterinary doctor, not involved in the study in any
other capacity, assessed video footage of the treated animals to provide an independent
QOL estimate.
4.2. Cell Biology Tests and Blood Parameters Determination
The cell biology tests used are the same as those described in our former publications
Raabe et al. [10], Zhang et al. [26] and Petridis et al. [53]. We focused on the impact of
collagen hydrolysates on the differentiation of chondrocytes as well as on the role of sialic
acids as contact structures of the cell surface as differentiation markers.
Blood samples were obtained from all dogs and horses under study in order to clarify
any existing medical condition. The blood samples were taken after stasis and disinfection
with 70% alcohol on the anterior vein cephalic with a 7.5 mL S-Monovette (Sarstedt) and
an attached cannula (Sarstedt). An amount of 16 IU served as anticoagulant Heparin.
The blood was centrifuged at 3000 rpm for 10 min after collection. A large blood count
(hematology), an organ profile and an IgG/IgM borreliosis antibody titer were created for
each dog in the Synlab Augsburg laboratory. Blood was drawn as part of the treatment.
The samples obtained were labelled and stored in a deep freezer until evaluation.
MMP-3: A mouse anti-dog stromelysin-1 monoclonal antibody MAC-084 (UCB Cell-
tech, Slough, UK) was used to coat the ELISA plates (Greiner Bio-One GmbH, Kremsmün-
ster, Austria) by incubation of 10 g/50 mL PBS buffer. After overnight incubation at 4 ◦C.,
the blood plasma samples were applied undiluted to the ELISA plates and incubated
at 4 ◦C for two hours. The second antibody, a rabbit anti-dog stromelysin-1 polyclonal
antibody (Biotrend Chemikalien GmbH, Köln, Germany) was added at a 1:8000 dilution
and incubated again for two hours at 4 ◦C. The last two-hour incubation at 4 ◦C was carried
out with a peroxidase-labeled goat anti-rabbit antibody (Sigma Aldricks, Saint Louis, MO,
USA) at a 1:20,000 dilution. The amount of bound peroxidase as a measure of the concen-
tration of MMP-3 present in the sample was determined using tetramethylbenzidine as
the peroxidase substrate. Three washing steps are carried out between each new antibody
coating in order to separate unbound antigens from the sample. The enzyme reaction was
stopped by the addition of sulfuric acid. Prostromelysin (UCB Celltech, Slough, UK) in a
concentration of 126 ng/mL was used as the standard. The resulting yellow color change
was measured at 450 nm in a Spectra Photometer (Tecan, Männedorf, Switzerland).
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TIMP-1: The ELISA plates (Greiner) were treated with an anti-dog TIMP-1 monoclonal
antibody MAC-080 (Celltech) in a concentration of 5.7 g/50 mL PBS buffer with incubation
overnight at 4 ◦C. The blood plasma samples were applied to the ELISA plates at a 1:7
dilution. After a two-hour incubation at room temperature on the Thermostar (13MG), a
rabbit anti-human TIMP-1 polyclonal antibody (Biotrend) in a 1:2000 dilution was used
as the second antibody. After a further incubation of two hours at room temperature
on the Thermostar, coating was carried out with a peroxidase-labeled goat anti-rabbit
antibody (Sigma) at a 1:4000 dilution. The amount of bound peroxidase as a measure of the
concentration of TIMP-1 present in the sample was determined using tetramethylbenzidine
as the peroxidase substrate. Several washing steps were carried out between each new
antibody coating in order to separate unbound antigens from the sample. The enzyme
reaction was stopped by the addition of sulfuric acid. Recombinant dog TIMP-1 was used
to generate a standard curve with a concentration range of 27.5 ng/mL. The resulting
yellow color complex was measured at 450 nm in a Spectra Photometer (Tecan) [49].
4.3. Statistical Analysis
Preliminary data processing started with Microsoft Excel (Office 2000 package, Mi-
crosoft, Redmond, WA, USA). The biomedical data of animals under study were evaluated
on the computers in the local computer network (LAN) of the Biomathematics and Data
Processing unit of the Veterinary Medicine Department of the Justus Liebig University in
Gießen. The statistical evaluations were carried out using the BMDP/Dynamic, Release
8.1 (Statistical Solutions Ltd., Cork, Ireland) [58] program package. Missing data in Tables
are marked with *. Consequently, the given entry is treated as a missing value by the
BMDP program. To describe the data, arithmetic means (x−), standard deviations (s),
minima (xmin), maxima (xmax) and sample sizes (n) were calculated and presented in a
table for quantitative, approximately normally distributed characteristics. The qualitative
characteristics were counted separately according to groups and presented in the form
of frequency tables. To statistically test the group and time influence for significance,
a two-factor analysis of variance with repeated measurements with regard to time was
carried out with the program BMDP2V in groups 1 and 2 with approximately normally dis-
tributed characteristics. If the values were missing, this was conducted using the BMDP5V
(so-called “forest test”). With regard to the quantitative characteristics, the group com-
parison of these two groups with normal distribution used the t-test and otherwise the
Wilcoxon-Mann–Whitney test (BMDP3D). For the semiquantitative characteristics, the
exact Wilcoxon-Mann–Whitney test using the “StatXact” program (V1, Cytel, Waltham,
MA, USA) was applied to compare the two groups. For the comparison of qualitative
characteristics, frequency tables were generated for all three groups with the program
BMDP4F. The qualitative characteristics were checked in the case of two expressions re-
garding significant correlations for each point in time only for groups 1 and 2 with the
exact test by Fisher. The Fisher–Freeman–Halton test was used for more than two values.
The “StatXact” program was used here (Cytel, 2010 [59]). The evaluation of the statistical
significance was based on the significance level α = 0.05; this means results with p ≤ 0.05
were given as statistically significant. In addition, the exact p-value was given, if possible.
Group 3, as a trailing group, was not included in the significance calculation.
4.4. Nuclear Magnetic Resonance (NMR) Spectroscopy
Proton NMR was applied to analyze the Fortigel collagen hydrolysate in terms of its
fragment size distribution (DOSY [7]) and possible identification of certain amino acid types
(TOCSY/NOESY). Mass-spectrometry and NMR previously provided a detailed molecular
analysis of the collagen hydrolysates under study [4,7–9]. In the NMR tubes, collagen
hydrolysates were dissolved at an amount of 3 mg in 0.5 mL water (90% H2O/10% D2O).
The NMR experiments were performed on a 600 MHz Bruker Avance III spectrometer
(Bruker, Karlsruhe, Germany) at 298 K. 2D-TOCSY experiments (DIPSI-2; mixing time 80
ms) and 2D-NOESY (mixing times 200 or 400 ms) were recorded with 512 (F1) × 1024 (F2)
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complex data points and a spectral widths of 7212 Hz (12 ppm). Water suppression was
performed using excitation sculpting and, per increment, 16 scans were accumulated with
an inter-scan recovery delay of 1.5 s. For processing we used zero-filling to 1024 (F1) ×
2048 (F2) data points prior to Fourier transformation, followed by baseline correction in
both dimensions. Spectra were calibrated on internal water.
4.5. Molecular Modeling
The structures of glucosamines, i.e., N-Acetyl Glucosamine (GlcNAc) and N-Acetyl
Neuraminic acid (Neu5Ac; also sialic acid) were downloaded from PUBCHEM (https:
//pubchem.ncbi.nlm.nih.gov/, accessed on 12 July 2019) in SDF format and imported into
the Maestro V. 12.3.013 (Schrödinger LLC, New York, NY, USA) [60] project table. Both
molecules were then sulfated using the Maestro molecular builder option. Their molecular
structures are presented in Scheme 1. An advanced conformational search for carbohydrate
side chain orientations were then carried out maintaining their 4C1 forms for GlcNAc and
GlcNAc-sulf and 1C4 for Neu5Ac and Neu5Ac-sulf ring conformations. The geometries
of five selected low-energy conformations of the four carbohydrates were ab initio (DFT
B3LYP 6-31G**) optimized (releasing all geometric parameters) with the Gaussian [61]
program (G09 version, Wallingford, CT, USA) and were then used as input ligands for
molecular docking into matrix proteins like MMP-3 and aggrecanases (e.g., ADAMTS-5),
present in the dog and horses organisms.




Scheme 1. Molecular structures of the carbohydrates in standard and sulfated forms. (A) 2-Acet-
amido-2-deoxy-D-glucopyranoside (GlcNAc); (B) 6-O-Sulfoxy-2-Acetamido-2-deoxy-D-glucopyra-
noside (GlcNAc-sulf); (C) N-Acetyl-Neuraminic Acid (Neu5Ac); (D) 9-O-Sulfoxy-N-Acetyl-Neu-
raminic Acid (Neu5Ac-sulf). 
The atomic coordinates of MMP-3 (2JT6.pdb [13]), ADAMTS-5 (2RJQ.pdb [12]) and a 
collagen fragment (1EI8.pdb [62]) structures were downloaded from the protein database 
and imported into Maestro. All protein geometries were processed (adding missing at-
oms, fixing bond orders, assign partial charges) by “Protein Preparation Wizard” of the 
Maestro program (V12.3.013, Schrödinger LLC, New York, NY, USA) [60]. 
The possible binding sites of MMP-3 and ADAMTS-5 were evaluated using the 
SiteMap program (V3.9, Schrödinger LLC, New York, NY, USA) [63,64] of Schrödinger 
LLC. The G09-optimized conformations of four ligands (Scheme 1) were docked into all 
SiteMap predicted binding sites of MMP-3 and ADAMTS-5 using the GLIDE program 
[65–68]. While flexible docking was considered for all side chains of the carbohydrates, 
the pyranose rings were fixed in 4C1 for 1C4 forms as stated above. All protein–ligand 
complexes resulting from GLIDE flexible were optimized (OPLS-2005 force field) and 
were tableted/ordered according their GLIDE docking scores. 
The HEX program [69] was used to generate and preoptimize the geometries of the 
MMP-3/collagen and ADAMTS-5/collagen supramolecular complexes. From around 100 
generated complexes the lowest-energy ones were selected for further molecular dynam-
ics (MD) studies. 
These HEX-output files were imported into Maestro and were processed by standard 
methods (as indicated above by “Protein Preparation Wizard”) to obtained the structures 
prepared for MD runs using the Desmond [60,70] program The OPLS-2005 force field (the 
up-to-date version of the OPLS force field family [71,72]) was used to carry out the simu-
lation studies. The protein–collagen complexes were initially solvated in Maestro (SPC 
water model [73] with the water molecules added within a 1 nm buffer around the pro-
teins) and the resulting structures were then minimized and equilibrated for 5ns. The final 
Scheme 1. Molecular structures of the carbohydrates in standard and sulfated forms. (A) 2-Acetamido-2-deoxy-
D-glucopyranoside (GlcNAc); (B) 6-O-Sulfoxy-2-Acetamido-2-deoxy-D-glucopyranoside (GlcNAc-sulf); (C) N-Acetyl-
Neuraminic Acid (Neu5Ac); (D) 9-O-Sulfoxy-N-Acetyl-Neuraminic Acid (Neu5Ac-sulf).
The atomic coordinates of MMP-3 (2JT6.pdb [13]), ADAMTS-5 (2RJQ.pdb [12]) and a
collagen fragment (1EI8.pdb [62]) structures were downloaded from the protein database
and imported into Maestro. All protein geometries were processed (adding missing atoms,
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fixing bond orders, assign partial charges) by “Protein Preparation Wizard” of the Maestro
program (V12.3.013, Schrödinger LLC, New York, NY, USA) [60].
The possible binding sites of MMP-3 and ADAMTS-5 were evaluated using the
SiteMap program (V3.9, Schrödinger LLC, New York, NY, USA) [63,64] of Schrödinger LLC.
The G09-optimized conformations of four ligands (Scheme 1) were docked into all SiteMap
predicted binding sites of MMP-3 and ADAMTS-5 using the GLIDE program [65–68]. While
flexible docking was considered for all side chains of the carbohydrates, the pyranose rings
were fixed in 4C1 for 1C4 forms as stated above. All protein–ligand complexes resulting
from GLIDE flexible were optimized (OPLS-2005 force field) and were tableted/ordered
according their GLIDE docking scores.
The HEX program [69] was used to generate and preoptimize the geometries of the
MMP-3/collagen and ADAMTS-5/collagen supramolecular complexes. From around 100
generated complexes the lowest-energy ones were selected for further molecular dynamics
(MD) studies.
These HEX-output files were imported into Maestro and were processed by standard
methods (as indicated above by “Protein Preparation Wizard”) to obtained the structures
prepared for MD runs using the Desmond [60,70] program The OPLS-2005 force field
(the up-to-date version of the OPLS force field family [71,72]) was used to carry out the
simulation studies. The protein–collagen complexes were initially solvated in Maestro
(SPC water model [73] with the water molecules added within a 1 nm buffer around the
proteins) and the resulting structures were then minimized and equilibrated for 5ns. The
final structures after equilibration were submitted for 50 ns NPT (pressure at 1.01325 bar)
molecular dynamics (MD) simulations with the Desmond program at 300 K. Molecular
geometries resulting from simulations were saved at 10 ps intervals and were used for fur-
ther analysis. These geometries (5000 altogether) from each simulation were exported into
pdb format and were used for analysis of interaction profiles using the PLIP program [74].
The xml files resulted from the PLIP calculation were imported into Microsoft Access for
analysis and data mining.
Schrödinger’s Maestro [60] was used for visualization of molecular structures, their
complexes and protein–carbohydrate ligand interaction profiles.
5. Conclusions
The experimental and computational methods applied were found to be useful tools
in providing valuable information on the relationship between therapeutic value and
mechanism. Such approaches will be key prior to these or other similar compounds being
adopted further as potential medical therapies.
Collagen hydrolysate and sulfated glucosamine and potentially the fatty acid and
vitamin rich food diet in the control group show similar benefits with respect to a treatment
of early osteoarthritis symptoms. The positive effects in all three groups seems to be
comparable, however, in contrast to sulfated glucosamine, collagen-hydrolysate provides
more options for an improved therapy. Collagen hydrolysates are defined mixtures of
short, long and medium-sized collagen fragments. Fortigel, used here, is a well-defined
collagen hydrolysate that can be considered the gold-standard. Our NMR and molecular
modeling techniques in combination with cell assays described here were essential in better
defining possible mechanisms contributing to the improvement of the dog-patients. Fur-
thermore, they provide a foundation for follow-up studies. These follow-up studies would
include further examining the effect of this treatment in other species (e. g. horses) and a
comparable analysis of various collagen hydrolysate compositions (e.g., fish skin, jellyfish).
We note that even if the collagen-hydrolysates are from one species their compositions can
be different depending on the formulation used by the supplier [8].
The positive effects we observed in the glucosamine (group 2) and the trailing group
(group 3) were not surprising given their known use in the treatment of osteoarthritis.
However, the clear and positive results in the collagen hydrolysate group (group 1) were
not predictable at the beginning of the study. During the 16 weeks study period muscle
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and leg circumferences increased and pain symptoms were significantly reduced with this
treatment. The study also clearly shows that there is variability among individual dogs,
with some reacting well while others react weakly to the nutraceuticals under study. Since
this may be based on the individual genetic makeup of the dog and subtle differences in
the stage of disease having a third option becomes a desirable option that may provide
added benefit to some animals. Additionally, sulfated glucosamine belongs to the standard
therapies in the treatment of early osteoarthritic symptoms while only limited information
exists about the molecular background of its beneficial effect, especially with respect to
the impact of the sulfate group. Additionally, in the case of collagen hydrolysate, which is
not part of a standard therapy, a number of structural questions which are related to its
therapeutic functions are still open. Therefore, we combined the feeding study with intense
molecular modeling calculations describing the stability of, e.g., complexes of MMP-3 with
the nutraceuticals of group 1 and group 2. These data have provided us with an initial
insight into unravelling key mechanisms of action for these compounds and avenues for
future study and for treatment.
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